About Us

Vésale

Vésale Pharma is a Namur-based company and a pioneer in the field of probiotics.  Since 1996, the company has been developing, manufacturing and marketing probiotic solutions based on the latest scientific discoveries. Proprietor of several strains and patents, Vésale Pharma markets a wide range of products in the digestive, pediatric, immune and women’s health fields. 

Thanks to rigorous selection of the probiotic strains used in its products, and a patented encapsulation process (Intelicaps) that enables probiotic strains to retain their metabolic activity, Vésale Pharma clearly stands out from the competition. 

2 new departments were created in 2023 with Superbiotics, selling probiotics in bulk and also in animal health.

Its products are currently marketed in Europe, the US, Asia and the Middle East through a network of distributors, and in Belux through pharmacies and parapharmacies.

1996

Creation

Vésale Pharma is born

1996
2012

Intelicaps®

In 2012, Vésale Pharma patented a probiotic micro-encapsulation process (Intelicaps®) that protects probiotics from humidity and heat. The process also protects bacteria from gastric acid and pancreatic juice without altering their functionality.

2012
2016

Development in Ghlin

In June 2016, Vésale Pharma inaugurated a new production unit coupled with its R&D activities in Ghlin.

2016
2017

PorcBiota project

(Wagralim cluster)

2017
2018

Phages

Creation of Vésale Bioscience, a spin-out of Vésale Pharma, dedicated to Phagotherapy

https://phage.health/

2018
2018

SuNup project

(Wagralim cluster)

2018
2022

Probiotics

In 2022, Vésale Pharma will pursue its research activities in 3 areas (women’s health, digestive health and pediatrics), bringing new products to market as early as 2022.

2022

R&D-based sales strategy

Vésale Pharma therefore relies on the development of innovative products to remain competitive. The products marketed by Vésale Pharma have the following characteristics:

  • They contain live probiotics, i.e. probiotics with metabolic activity
  • The strains are scientifically documented. For each strain, Vésale has compiled a monograph containing several relevant scientific publications demonstrating the benefits of these strains.
  • The strains are resistant to gastric acidity and bile salts, preserving their functional capacity right up to the intestinal site thanks to the Intelicaps encapsulation process.
  • They target various areas: digestive health, women’s health and immunity (the latter is scheduled for launch in 2022).
  • They are manufactured in the form of semi-finished products: premixes or finished products: standardized or custom formulations (personalized/tailor made).

Unlike suppliers of large probiotic solutions, Vésale has the flexibility (“agility”) to rapidly adapt the composition and galenic form of its products (capsules, sachets, oro-soluble powder, tablets, chewable tablets or liquid form) to enable them to be administered to every member of the family (including pregnant women).

Our Team

Meet our team

Jehan LIENART

CEO

Eric POSKIN

Spokesman

Jacqueline ABRASSART

Finance & Admin Director

Charlotte LIENART

BELUX Director

Titouan VESTERS

Chief Operating Officer

Marleen Van D'huynslager

International Sales Director

France FANNES

Collaborations & Corporate Compliance Director

Adrien BERGER

QA-RA & Project Manager

François DAL

Supply Chain Manager